Taiwan Bio has entered a partnership with TRACT Therapeutics to advance a cellular therapy for the prevention of allograft rejection in solid organ transplant. The partners will launch a multi-center Phase 2 trial investigating the reduction of immunosuppressant drugs in living donor kidney transplant recipients in both the U.S. and Taiwan.

The partnership leverages Taiwan Bio’s expertise in cellular therapy manufacturing and TRACT Therapeutics’ immune modulating regulatory T cell therapy platform. By combining their strengths, the companies are set to explore new frontiers in enabling allogeneic tissue transplant with a focus on enhanced patient outcomes and improved quality of life.

The Phase 2 trial builds on promising Phase 1 results which demonstrated an excellent safety profile and encouraging efficacy signals with TRACT’s autologous Treg product, TregCel. The Phase 2 clinical trial represents the first collaborative effort between the two companies.

“We believe that this collaboration holds tremendous promise for patients seeking better therapeutic options,” said Cyrus Yang, COO of Taiwan Bio. “Together with TRACT Therapeutics, we can bring a synergy of technology and experience to accelerate the development of transformational Treg therapies.”